Statement: On days 1-7 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV.
Primary_evidence: INTERVENTION 1:    Dexamethasone + Ondansetron IV   All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.   Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride). INTERVENTION 2:    Dexamethasone + Palonosetron IV   All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.   Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).